.(Q,01\liE\:$
`llQJA'DIS,'llQ)\W,QMf'l .llliES~~~SE~i!l~ ~
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`
`March 18, 2022
`
`THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
`THE RECORDS OF THIS OFFICE OF:
`
`PATENT NUlVIBER: 9,46.J,1.J0
`ISSUE DATE: October 11, 2016
`
`By Authority of the
`Under Secretary of Commerce for Intellectual Property
`and Director of the United States Patent and Trademark Office
`
`Certifying Officer
`
`Miltenyi Ex. 1001 Page 1
`
`

`

`I 11111 11111111111 11111 111111111111111 IIIII IIIII IIIII IIIII 111111111111111 IIII
`US009464 I 40B2
`
`(12) United States Patent
`June et al.
`
`(JO) Patent No.:
`(45) Date of Patent:
`
`US 9,464,140 B2
`*Oct. 11, 2:016
`
`C /2N 15185 (2013.0J): A61K 2039/505
`(2013.0 1); A6JK 2039/5/56 (2013.01): A6/K
`103915158 (2013.0J ): A61 K 2039/585
`(2013.01); C07K 1317/611 (2013.01): C07K
`1317/ 80 (2013.01 ); C07K 13/9/00 (2013.01 ):
`C07K 1319102 (2013.01): C07K 2319/03
`(2013.0 1); Cl2N 250//515 (2013.01); ,cnN
`2510/00 (2013,()1); Cl 1N 2740/1'5034
`(2013.01 J; crm 274f/lJ5043 (20 t3 .0J)
`(58) Field of C lassification Starch
`None
`Sec application ille for complete search hls101y.
`Refereuccs C ited
`
`(56)
`
`(54) COMPO SITIO1"S ,\.','D METIIODS FO R
`T REATl\mNT O F CANCER
`
`(71) Applicam: T he Tr ustees of the University of
`Pennsylvania. Philadelphia, PA (US)
`
`(72)
`
`Invcnh)r$: Car l B. Ju ne, Merion Station, PA (US):
`Bruce L. Levine. Cherry l lill, NJ (US);
`David L. Portct-. Springfield. PA (US);
`M ichael D. K atos, Phlladelpliia, PA
`(US): M ichael C. M ilo ne, Cherry Hill.
`NJ (US)
`
`(73) As~ignee; T he 1\-ustel?S uf the Un iversity uf
`Pennsyh,aniu. Philadolph.i:i. PA (US)
`
`( "J Notice:
`
`Subject lo ,my disclaimer. (he (erm l1fthis
`patent is extended or adjusted under 35
`U.S.C. 154(h) by 0 days.
`
`·Th.is pateut is subject to a ten11iual dis(cid:173)
`~laimcr.
`
`(21) Appl. !No.: 14/996,95:l
`
`(22) Piled:
`
`.Jan. JS, 20.16
`
`(65)
`
`Prior P ublication Data
`us 2016/0130355 '\1
`
`May 12, 2016
`
`Related U.S. Applic~tion Data
`
`U.S. PATENT DOCUMENTS
`
`5,359,046 I\
`5.686.2St A
`5,712, 149 /\
`5.S74,240 I\
`5.906.916 A
`6.103.521 A
`6,J JC/.494 Bl
`(i,355,779 BI
`6.4I0.319 Bl
`6,569,991 Bl
`7,049, 136 132
`7,052.906 BL
`7 ,070,995 132
`7,265,209 !32
`7,319,143 !32
`7 .320,787 B2
`7,402.43 1 B2
`7 .446.190 132
`7,446.191 82
`
`1011994 C'npon ct 3f.
`ll/1997 Robeti:s
`t 1998 Robcns
`2/1999 Ni <!l al.
`5/J 999 Eshhar ct al.
`lV:!000 Capon ~I al.
`J 111001 Capon ct al.
`312002 Goodwin ct al.
`6/2002 Raubitschek cl al.
`5/2003 Kwon
`512006 Seed c1 al.
`5/2006 l awson d al.
`71W06 Jensen
`912007 Jensen
`1•2008 Gross el al.
`li200li Seed el 111.
`7 12008 l lar-Noy
`1Ji2008 S:tdclain t'f al.
`( 112008 Jensen
`(Continued)
`
`FOREJGN PATENT DOCUMENTS
`
`0574512 13 I
`2/2003
`l 226244
`712004
`(Contiu11c.xl)
`
`OTHER PlJBI ,TCATIONS
`
`A NCBJ Direc1 Submission NP 000725 dnJcd i'iov. :!l. 2()1().
`A NCBI Oirecl Submission NT• 932 170.1 dated Nov, 21. 20 I 0.
`Backsgaard el al.. "Acute tumor lysis syndrome in solid rurnOJ1'-a
`case report Md review of the liicr;,ture." 2003, C,ioccr ChcrnoHier
`!'hannacol., 5 l, lt.7-92.
`Romla11za ct al .. "Suicide gene I herapy o f g.rnf1-versus-hoSL d.isease
`iJJdl1ced by conlntl memo1y buman T lymphocytes," 2006. B lood
`107: 1828- 1831\,
`
`(Continued)
`
`Primar.i• Examiner - Michael Burkhart
`(74) Allvrne_i'; Agent, or Firm - Saul Ewing LU';
`Kathryn Doyle
`
`A BST RACT
`(57)
`·n1e present invention provides compositions and methods
`for treating cancer in a human. Th" invcmlion inc:ludcs
`relates 10 admi nistering a genetically modified T c,e.Jl to
`express ,i CAR wherein the CAR comprises ru1 autigen
`binding domain, a lr.:lllslllerubrane domain, a costimullatory
`signaling region. and a CD3 zeta signaling domain.
`
`28 C laims, 2 6 Drawing Sheets
`
`(63) Contiou(1tinn nr application No. 13/992.622 . .filed as
`applic;:1tion No. PCT/US20 1 l/064191 on Dec. 9.
`2011.
`
`(60) Provisl1011al applic.ition No. 61/421.470. filed on Dec.
`9. 2010, provisional applica1ion No.61/ 502,649. filed
`on Juu. 29, 2011.
`
`EP
`llP
`
`(51)
`
`(52)
`
`(2010.0l)
`(2010.01)
`(2006.01)
`(2015.01)
`(2006.0l)
`(20 15.01)
`(2006.0l)
`(2006.01)
`(2006.0 I)
`(2006.01)
`(2006.0 l)
`(2006.0J)
`(2006.01 )
`(2006.01)
`(2006.01)
`
`l nt. CII.
`C12N 5/071
`C12N 5/0783
`C12N 5122
`A61K JS/14
`C07K 161'28
`A61K 15117
`A61K 39/(}0
`A61K 191395
`C/2N 15185
`Cfl7K 14/705
`A 61 K 48l()(J
`C(J7K 141525
`C(J7K 141725
`Cll7K 16/3()
`CJ2N 7/fl(J
`U.S. Cl.
`ere ........... Cf/7K 16/1896 (2013.01): A6/K 35/17
`(2(H3.0J); A61K 39/(l(}JJ (2013.01); A61K
`.l9/39558 (20 13.01); A61K 481005 (2013.01);
`C07K 14/525 (2013.01); CfJ7K 1417051
`(2013.0J ); C(l7K 14/711517 (2013.0l ); C() 7K
`14170578 (2013.01): C07K 14170596
`(20 13.01)~ C07K 16/3061 (2013.01); C12N
`5/(1636 (2013.0 1 ): CJ2N 710/J (2013.01):
`
`Miltenyi Ex. 1001 Page 2
`
`

`

`US 9,464,140 B2
`Page 2
`
`(56)
`
`References Cited
`
`U.S. PAJENT DOCUMENTS
`
`7.514.537 [l2
`7.74 1.46:i Bl
`7,994.298 82
`8,2 11,42:! B2
`8,252,914 82
`8,389.282 82
`8,399,645 B2
`8.465,74:l Bl
`2003/0060444 A I
`200310077249 A I
`2()(JJ/O 14898:! A I
`200410038886 /\ I
`200410043401 Al•
`
`4100!1 ,k-nsen
`6!2010 1: shhar et al.
`81.201 1 Zhang cl al.
`l~ hhar d :ti.
`7120 [2
`8,120 [2 ?Jiang el al.
`312013 Sa.lelain el al.
`'.\ '20 lJ Campana et al.
`611013 Roscnoc1-g ct a I.
`3/ 2003 Finney c1 al.
`4 12003 Bebbington el al.
`S 2003 13renner et al.
`212004 Finney et al.
`'.lt.2004 Sadelain ......
`
`200510 113564 Al
`2005'012967'1 Al
`200810131415 Al
`20091025 7994 A I
`201()10.233200 A I
`201110052554 Al
`lOll/014855:! ,\I
`2013 007141•1 Al
`20131014933'1 AL
`
`51W05 Campana <'l nl.
`6.12005 Cooper 01 al.
`6,·wox Riddell ct al.
`1011009 Jensen
`9120 [0 Medin
`312011 Zakrzewski e t al.
`612012 Jensen
`312013 Dolli el al
`61201) Cooper el a.I.
`
`C071 l 2 l 104
`43516 ,]6
`
`FOREIGN PATENT DOCUMJ1NTS
`
`r,p
`871495
`JP
`2003-5.1730J
`2004-529636
`JP
`WO'/11 I 5322
`WO
`\VO
`W0/9513 0014
`WO
`\\1096/238 14
`W096/2467 I
`WO
`W0/97115669
`WO
`W<),'971236!3
`WO
`WO
`W09$/ l 8809
`W099100494
`WO
`WO
`W099l 57268
`W0/00/ 14257
`WO
`WO 01134841
`WO
`WO
`W 0 102/33 I O l
`WO 02:077029
`WO
`W<;)l021077029
`WO
`WO
`WU '021088334
`WO
`W02005l0 19429
`WO WO 2 00S1044996
`WO
`W0200610G0878
`WO
`\V0200ll,045437
`WO
`W02009/09 l 8,6
`WO W0/20101025(77
`WO wo,20 w. 085660
`W020 L 1/059836
`WO
`WO
`W02012/0J3885
`WO
`W02012/0.58460
`WO
`W02012.'08284J
`WO
`W02012/127464
`W020121 I 35k54
`WO
`WO
`W020l2/ U885S
`WOl O 13/033626
`WO
`WO
`WOlOIJ.1040371
`WO
`W020131059593
`
`6 12005
`512003
`912004
`9119i>2
`IJ/[995
`$11996
`8i1996
`5 · 1997
`7, 1997
`5, 1998
`111999
`1111999
`J /2000
`5 •2001
`4/2002
`l0/2002
`l012002
`11 /2002
`312005
`5,2005
`6 ·2006
`4,200s
`7tl009
`J120IO
`712010
`5 2011
`3 120 12
`.512012
`6/ 2012
`9120 12
`1012012
`10120 12
`312013
`3 ·201J
`4'20 13
`
`OTIIER PUBLICATIONS
`13,~nljens et al ... "Eradicntlun o r systemic B-cdl lumt>rs by geneti(cid:173)
`cally ta.rge1ed lhum:in T lymplwcytes cu-stimulated by CD80 and
`inlerleukin-1 5." 200'.l. Na111re Medicine. 9(3): 279-286
`Brent_jens et al.. "Crendically tars,eted ·1 cells era((icale sys1emic
`acute lymphohlastic lcukc,mia .xcnogrnfis." 2007, Clin Cancer Res
`I 3:54i6-5435.
`Brenljens cl al., .. Safely and persistence of adopli vely transferred
`m11ologo11s CD l9-targeh .. -d 1 cells in paticms with i·elapsed or
`leu.h·mias," 20 I J
`chomothcrnpy
`rcfracwry 8-cul l
`131ood
`1 IS(18);4817-41S2~.
`
`Bn,nljcns Cl al .. "Trealmenl uf ch.rook lymphocytic lcmkcmia wiih
`genetically target<-.! aulologous T coils; Ctl.SO repur1 or a.n u1l10:res~en
`adverse <!Vent in a phase I clinical trial." 20 I 0, M9I Ther, I$, 666-8.
`Brent,iens. cl ,tl. '";\ Pba"" l Trial for the rreaurn.•nl of C'hemo(cid:173)
`refracto,y Chronic l,ymphocyl ic Leukemia wilh Ci) IQ."fargeiet.1
`Aulologou, 1 Cells.'" Mol. fherapy. 200~. p. S 15, vol. l6, Suppl I.
`Brocker and Karjalaincn . .. Sig,1mls Uuouglt T cell receptor-!; chain
`alone ore insufficicnl to prime resting T lymphocytes." 1995. JI. Exp.
`Moo .. !Sl: 1653-1659.
`Call. el al., ·'The T cell t<.'Ccplor: critical rol<: or the membrane
`environ111enl in receptor assembly and funciion." 2005, An nu Rev
`lmmunol . 2005, 23:JOJ-125.
`Campana et al .. " ]'-Cell lmtmmc,Lh~rapy for l:l-Linengc Acute
`Lymphoblastic Leukemia Csing Chi111erk Anlii;en Receptors fha_l
`l)~livcr 4-188-Moointed Coslimulaio,y SigMls'' 200J Blood
`J 02( 11 ); abstmct 112:!'.I.
`Oupenilo el aL. --conlJ'ol ot' la.rg.c. established tumor xcnografls
`with gcnclicitlly rcl/lrgct<XI human T c0lls containing C'D28 am!
`CDJJ7 domains." 20()(). Proc Natl Acad Sci US A 106;3360-3365.
`Davila et al.. "B Cell Aplasi.i in a Patient with Relapsed 13 Cell
`/\cute Lymphoblaslic Leukemia followi ng Rc-rnductio n and Con(cid:173)
`solidation with Aulologous I Cells Genetically l;ugeled tu the
`CD l9 Antigen." 2010 ASH Meeting Abstract No. 3268. presented
`Dec. 6. 2010 (posh,r abstract).
`Davila et al., '"f Cells Genetically Tru·getcd 10 C'l:>t!) P.ra.clii;.11c
`13-J\Il in 8 No~cl Syngcneic Mouse Discas<1 Model." 20W ASII
`Mceling Abstract No. 17 J. pi~scnteo Dec. Ci. 20]() tposlcrabst.rnct).
`l)ohncr el nl., "p53 gene deletion predicts for poor survivl!ll an,I
`non-response tu therapy with purine ,l.Jlnlogs in chronic B-cell
`leukemias." 1995, Blood. 85: ISR0-9.
`Dropulic el al., '"Genc-ba~cd 1mmunot.hcrapy for human i1111111uno(cid:173)
`delicicncy virus infccllo n and acquired ,mmunodeliciem:y Syn (cid:173)
`d.romc." 2006, Human Gene Therapy. 17; 577-88.
`l)ul l el al .. "A rhird-generation leni-ivims vector w ith ~ con/1 itiomtJ
`packaging syslcnL·· 1998. J ViJol, 72: l!46J-7 l.
`6shb:u e t al.. " Specific activatiun and targeting of cytotoxi<: lym(cid:173)
`phocyte~ through chimeric si1tgk chains consisling <>[ antirbody(cid:173)
`b inding domains aud lhe Y or!; subunits uf I.he immun()globul in and
`T-cell rccoplors." 1993, Proc Nall Acad Sci USA 90;720-724 .
`FiMey el al .. "'Activation of resting human primary T cells with
`cltimeric r<-ceplors: coslimulaJion from CO2~, inducible cosliunula(cid:173)
`lur. CD l34. and C0 l 37 (4-IBBJ in series with signals from the
`TCR zela chain." 2004, J. lmmunol 172: 104-113.
`Finney et al.. "Chimeric receptors providing both primnry and
`cos1i111ulatory signaling in r cells from a single gene pmducL"
`1998. J lmmunol 161 :2791-2797.
`FricdmnM-Morvinski cl at.. "Rcdirecl'cd pr1m:uy T cdls harboring
`a chimeric receptor .rcquin; co~limulnlion for lhdr anl1gc11-,;pecuic
`aclivalion." 2005, Blood 105:3087-3093.
`Geiger a11d Jyolht, ''Devclopmenl and applicalfon of rnc.cplor(cid:173)
`lymphocytes for adoptive 1mmunotherapy." 200 I,
`modifietl T
`Transfusion Mcd.icine Reviews. IS(l): 21-34 .
`(icigcr cl al .. ·'tntcgraloo src kinase aml constimulntory a,ctivity
`enhances signal transduction through single-ch;un chimeric rec~l'(cid:173)
`tors in T lymphocytes." 2001. Blood 98lS):2364-7L
`Gilham et al .... Primruy Polydonal lluman T lymphocytes tugclcd.
`l.o carcirlo-cmbry,mic anligens ;md neural cell adhesion mo•kcule
`tumor a11ligens by CD31;-bas~d chimeric immune receptors." 200 I,
`J, ln111m11ology, 25(2): 139-151.
`Gong el at.. "Cancer p,1lienl T cells genet ically liirgetetl Lu prostale(cid:173)
`spoeifit 111<\mbrfiocJ ruili!;~n specifically ly,;e pro~tall! c:1necir cells
`and release cytokincs in re.,;ponse 10 prostnlc~spccific memhmne
`antigen.'' 1999,Ncoplasia, 1(2): 123-127.
`Uribben cl nl., '"Siem cell tmnsplantation fur inclo!e nl lymphoma
`a.od chronic ly mphocylic leukemia:· 20 11 , Biol Blood Mlarmw
`Tmnsplnnt. 17: Suppl :SCi3-S70.
`Grilliri el al., "Development itnd appUcalioo of ~llrface-linkcd single
`chain antibod.ies against T-cell antigens." 200 I. J . l.mn11lIJologica.l
`M~'llloJs. 248: 77-'JO ..
`Gross and F.shha.r. 1992. "F.,ndowing T cells with a_ntibody speci(cid:173)
`tidty using chimeric T ,ell receptors." 1992, FASEB J. 6; JJ70-
`JJ7$,
`
`Miltenyi Ex. 1001 Page 3
`
`

`

`US 9,464,140 B2
`Page 3
`
`(56)
`
`References Cited
`
`OTl-1.ER PUBLICATIONS
`
`I l:,llek et al., .. (,~iddincs for the diagnosis Md trcatmenl of cluo oic
`Jyrnpboc)'l.ic lc1ukcmia: a report fro,n Lhe lnlemmionalWork~bop on
`Chronic Lymp,hocytic Loukllmia updating the Nalionnl Can<:er
`lnslitule-Working GroLLp
`1996 guidelines."
`2008, Blood
`11 1 ( 12):5446-5:456.
`lkkclc cl 11L, "1(1foW1h retardaJion ofl\llllOfS by adoptive tmnsfer of
`<..-ytotoxic T lymphocytes reprogrammed by CD44v6-specific
`~cl'v:zcw-chimcra." 1996, Int J Caneer 6k:232-2J8.
`llo ct al., "Ado'[llive lmmunolhempy: 11nginecring 'I .:ell rcsJ)(" nses
`as biological \\lc:,pons for tumor mass destniction.'' 2003, Cancer
`Cell 3:43 l-437.
`Hollyman c t nl .. ··Manufocluring Valiclalion of Biologically flunc(cid:173)
`tional T Cells Targeted to CD19 Antij!,en for Aulolog1,us Adoptive
`Cell lnerapy." .I. ln1111uno1her .• 2009. pp, 16!/- 180, vol. 32, ~o. 2.
`Hornback ~~ aJ., -~rhe Recomblnanl T Cell Recep(or Slralei;y:
`Insight~ inlo StnK·l11rc nnd Function ofRccombinnnl lmmunorecet,(cid:173)
`lors on the Way 1owards an Op<imnl Reccplor Design for Cellular
`lmmnnothcrapy," 2002 Currcnl Gene Therapy 2.2 11-226.
`Lmai ct al.. "Chimeric recl-;.,tors with 4-IBl3 sigualing capacity
`provoke pokol cylotoxlci1y against acute Jymphob(agtic leukemia."
`2004. Leukemia 18(4):676-684.
`Imai el al., 2005, Genetic modificntlon of primary MlLU'al killer cells
`overcomes inh:1bi101y signals and induces specific killing of leuke(cid:173)
`mic cells. Bloc,d, 106:376-383-
`JntcmaJiona.1 S•Nuch Report for PC'flUS20 J l,0li4191 tlaled May l,
`2012.
`Irving & Weiss. ·"lb" cytoplasmic doma.iit oft.be I' coll receptor zcli!
`chain is i;utficie ot 10 couple to r~-ccpto r-asst1ciaK'<l signal transduc(cid:173)
`tion pathways." 199 1, Cell 64:891-901.
`Jena cl al., "R<:d.irecl.ing T-cell sp~cilic il)' by introducing a ILUnor•
`s pecific chimeric antigen rccep1or." 2010, Blood. 116: 1035-44,
`Jensen el al.. ""Anlilra.nsgene Rejection Responses Con1ribulc to
`Altenualed Pe,rsistence or Adorlivcly Transferred CD20/CI) 19-
`Specific Chimeric An ligcn Receptor Reclirccted T Cells
`in
`Humans." 20 10 Biol Blood MnrrowTransplMI 16;1245-1256.
`Johnson et al.. "Gene lherapy wilh hum.to :md mouse 'f-cell recep(cid:173)
`tors mediates cancer rcgrc:,,~ion Md targcls normal Ussues c.-<press(cid:173)
`ing cognate antigen." 2009, Olood. 1 l4: 535-46.
`June et al.. "Engineering lympho,ytt: subsets: tools. trials and
`1.rib11lalions.'' 2009. Nat Rev I.Jllll1llno l. 9: 704-16.
`Kalos, ct ,ti., "T Cells with ChimcricAnligen Receptors Have Potcnl
`Anlitumor l'!Jfocls and Can l:,s1ablish Memory in l'a!ienls with
`Advanced Let1lkcmia." 101 1, Sci Transl Me<l 3(95):95ra73.
`Kcr.ahaw <:I at, "A ph:1sc 1 study on adoplive i1rm1unollmrnpy using
`gene-modified T cel ls for ovaria/J cancer.'' 2006, Cli n Cancer Res
`12:6106-611~.
`Kim et al.. --111um,1n 4-IBB regulates CD28 co-stimulntion to
`promote Tbl cell responses," 1998, fau· J 1Jiun1,mol 28:8~1-890.
`Kochenclerfor c,t al.. "Cons1.ruction and Pre-clinical Eva.luation of an
`Anli-CO19 Chimeric Antigen Receptor." 2009, J IJ11munothcr
`32(7)6il9-702.
`Kochenclerler, d nl., "A PhaNc r c'linicnl ·1ri,tl of rrentmenl or
`B-Cell Malignancie.~ wi1h Autologous A.nti-CDl9-CAR(cid:173)
`Tran5dllc~-d T Cells.'' 2010 ASJ-1 Mccling Ahslrnd No. 2~65,
`prcSWllCd Dec. 5, 2010 (p():\l<'r nbslracl).
`Kochcndcrfor, ct al ., "Adopliw lrnnsfcr of syngeneic T cells
`lians<luced with n chiJl'lefic nntigcn receptor IJrnl recognizes murinc
`CD 19 can cradjcate lympl1oma and normal 8 cells." 20 I 0, l31oo<l.
`J J 6(9)3875-38:&6.
`Koehcnderfor. •et al., "Etadicat.lon o f B-li neagc cclJs and n:gn:s~ion
`of lymphoma i n a pa1jenl treated with aulologous T cel ls scnetI(cid:173)
`ca.lly--cnginecrnd lo recognize CD19." 2010. Blood l 16:409!/-4102.
`Kocbcnderfer, ,21 al,, '·Novel l\ntigcn-Sp<..>cific 11-cpnnsioo ofT Cells
`'l'ra.nsduced willh a ('1) 19 Ch imeric Antigen Receptor." 2010 ASH
`Mectln_g Abstracl No. 3262. pn.,.ented l)ec. 6. 2010 \poster
`abstract).
`Kohn, cl' al., ''C,\Rs on trnck in the clinic ." 201 I, Moleculru· Thcr
`19(3 ):432~3l:i,
`
`Krause el a.I .. "Anligen--dcpend.cnl CD28 signaling sel<-"<:ti~ely
`0nh1U1ces s urvival and rroliJcra1ion in g.:ncti,ally mod.i.fied acti(cid:173)
`vated h uman pri111nry ·1 lymphocytes: · 1998, .I. fap. Med., I 88(4):
`6 IC)-626.
`l runanna et al" "l'cntostalin, cyclophosphamide, and ril'lLximab is
`an active. wdl-toleraled regimen for patients wilh previously
`treated chronic lymphocytic leukemia." 2006, J Clin Once,!, 14:
`1575-$1.
`Lamers er :ti .. ''Trea1,n~nt oJ' metastatic renal cell carcinom:1 with
`aulologous T-lymphocyles genetically retargcted against carbonic
`anhydmsa IX: first clinical e.~p<'rien~e." 2006, .l ( lin Oncol 24·e20-
`e22.
`f.apo1t el al., "Ad<lpl.ivl.' lransl<>r of costimulated I ~ell~ induces
`lymphocytosis in p;lLienlS witl1 relapsed/refractory non-Hodgkin
`lymphomn following CD:.4+-sdedcd hcm,1lopoietic cdl lransplnn(cid:173)
`tation." 200;1, nlood 102, :?004-2013.
`lee ct a.I.. "In vivo inhibilion of human CDl9-targcted clfoctor T
`cells by nan,rnl 'l' regulatory cells in~ xenolransplanl m11rinc model
`of B cdl mali!].llllllcy," 20 11. Cancer Res 71 :2871-2881.
`Le1ourn<lur & Klausner, ''l'-ccll and basophi l activation through the
`cytoplasmic tail ofT-cell-rcceptor zcta family pl'Oteins.'' t \)9 ( _ Proc
`Nnll Acad Sci US A 88:8905-8909,
`Levine el a.I.. "Ot.'ne lransler in humans usin!,?. a cMditionally
`replicat ing lcnlivirnl vector." 2006. Proc ~nil J\catl Sci ll S A
`J 03: I 7372- 17377.
`Maca.llan cl al., "Measurement anti modding. o f human 'T cell
`k1J1ctics:· 2003. Eur J lmmunol , 33: 2J 16-Ui,
`Maher ci al., "I lutmn T-lymphocytc cytotmdcity and pro Ii fm11ion
`d.lrod~'<I by a single dwneric TCR:re1a / CD28 rtlceptor:• 2002, Ka.t
`Biotcchnol 20(1 ):70-5.
`McGuinncss. el al.. "Ami-tumor ac11vily of human r cells express(cid:173)
`lng the CC-IIJ-ze~1. chimeric Immune receptor." 1999, Hull11.Gene
`Ther JO: 165-l 73.
`Milone et aL, "Ch imeric receplors cootaining C-DIJ7 signnJ
`lransductioo do nL'J.i ns iued ialc enhanced survival of 1 cellls anti
`increased
`itntilcu.kemic efficacy
`in vivo.'' 2009, Mot
`!'her
`17(8): 1453-64-
`Molina. "A decade o f riluximab: improving survival outcorn<'s in
`non-Hodgkin's lymphoma." 200$. Ann Rev Med. 59: 237-50,
`Morgan ct al .. "Case repprt of a seriol!S adverse ev'-'nl following the
`admin istrnlion ofT cells lmns1lu<:ecl with a c himeric antigen recqJ(cid:173)
`tor n!cog.ni:ting ERBB2." 2010. Mol Ther. 18: ll43-51.
`Morit-z &. Umncr, ''A s pacer region hdwccn lhc single .:hain
`antilxldy- Md the CD3 ✓.cl'n-ch:iin domain of chimeric T cell
`recep1or compone nts is required for .:tlicient lignml bindin.g and
`signnling activity," 199~. Gene 111cmpy, 2:539-546.
`Moritz cl nl.. "Cytoto:(tC T lymphotyles with n gralled rccog:nition
`specificity for E RJ3B2-e:<presslll~ tumor cells" 1994, Proc. Natl
`Acnd. Sci. 91:4318-4322.
`Naldini el al.. "In vivo gene deliv.:ry and slable transducl ion of
`nondlviding cells by a J.:ntiviral vector." 1996, Science. 272: ,263 -7
`Nic holson, cl a.I .• ··coastrnclicms :Ind Cha.radtlrizniion of a Punc(cid:173)
`lion;u (1)19 Specific Si ogle Chain Fv Frngmcnt for lnununolhorapy
`ofB Lineage l.eukcrni3 and Lymph oma.'' .\,fol, lr,11mu10I., 1\197, pp.
`11.57-J 165, vol. 34. ~o. 16-( 7,
`Ochoa ct al., lmmunc Defects Ln T Cells From O mccr Pa.tie nls,
`Parallels In lnl<'Clious Diseases, from: Crulccr Jmmunolhc~~py 11t
`thl' Cwssroad.s: how 11uno1·s evade immunity and what ~-,U) "1: done
`{curren t clinical oncology), ~clilc'(( by James H. Finke, Romdd M.
`Bukowski 2004 •~1ilion.
`Park and Btenljeng. "A<lopliV<' lm1i1unothM1py !br B-cell Malig(cid:173)
`nancies with Autologous c himeric Anligcn Rcccplor Modified
`Tumor rargcte<I 'I' Cells," 2010, l)iscov Med 9(47):277-2~8.
`Pnrk el 11I.. "Adoptive tnmsfer ol' chimeric antigen receptor re(cid:173)
`dlrcclcd cytolyttc T
`lymphocyte clones
`in pntlco1s with
`neuroblastoma .'' .2007. Mol lnc.r 15:82.5-833.
`Patel c1 al .. "Impact of chimeric immune re.:ep(or cxtrac,ollulat
`protein doma.Uls on T ceU fum;tion." I 998. Gene Th.:rapy. 6,
`412-419.
`Portl!r el al. ·•A phase I trial of do no r lymph ocyte inflisions
`expanded and aclivaled t:X vivo -via CDJ,CD28 eostimulillion."
`2006. 131011d, l07; 1325-J J.
`
`Miltenyi Ex. 1001 Page 4
`
`

`

`US 9,464,140 B2
`Page 4
`
`(56)
`
`References Cited
`
`OTHER PUBLJCATIONS
`
`Portor e( al ,, Chimeric Antigcu Receptor 1 herapy for B-ccll M3lig(cid:173)
`nancies. 10 I I , J Cancer 2 :33 l -332.
`Porter. "Chim<!fic an1igcn r,-ceptor-111odi6ed r culls in chronic
`ly mphoid leuJ«,mia." 2011 New England J Med 365(8):725- 73:l.
`Pul~ et al,. " Virus-specific T cells engineered to C\>CXpress tumor(cid:173)
`specific Jcccpt<1rs: pcn;islcncc and :mtilumor ru:fivily in individual s
`with neuroblastoma," 200l!, Na1 Med 14: 1264-1270,
`Rapopon er aL. "Restoration of immunity in lymphopenic individ11-
`nls with cancer by v:icdnalion and ndortive T-ccll lr:lllsfer," 2005,
`Nal Med ll: 12:30-1237.
`Rocdcrer, "T~,:11 dynamics ofinununottdi,;i,;ncy," 19'15, Nat Med,
`.I : 621-7
`Romeo & Seed. "Cellular [m:munity to 1IJV :iclivnlctl by CD4 fo,.,d
`lo TceH or Fe r.c~p1orpolypeptidcs.TI L991.Cell 64: L037- J046.
`Sabbagh el al., "11':F (iunily ligamls tlefwe oiches for ·1 cell
`memory.'' 2007, 'frends lmmur\ol 28:333-339.
`S3dcl:tin cl ~1" ·•targeting 11.u110111s w ith gcoelie,11Jy enhance~ l
`ly111phocy1es:· 2003,Nal Rev Cancer J(l):35-45.
`Smklain L1 al., "The promise and poteoti;J pitfalls of chimeric
`antigen recL"J)[Clrs." 2009. CtuT Opin Immunol. 11; 215-:!3.
`Savoldo cl al.. "CD28 cos1im11lation impiovcs expansion and pcr(cid:173)
`Kistenceof chirneric antigen receplor-mo11ifietl Teells in lymphomn
`patients.'' 201 1. J Cliu Inwsl 12 1(5): 1$22-6.
`Sebestyen, cl al .. "Human TC'R lhnl in<'oll"oratc CDJzetn induce
`highly pn•fem·d pairing between rcRnlpha and beta ch.tins fol(cid:173)
`lowing gene tmnsfer." 2008. J lmmunol. 2008. 180( I i ):7736-46.
`Song. cl al. ''C'D27 costimutation nugments lhe survival and anti(cid:173)
`tumor Bl'livi1y of redirected human T cells in vivo." 2011 Blood
`119:696-706.
`Sorror el al., "<Outcomes after ollogcncic bcm111opoiclic cell trans(cid:173)
`pl:tnrnlion with nonmycloobla1ivc or myeloablalivc conditioning
`n!timens for i.reatmcnl of lymphoma nnd Chronic lymphocytic
`leuk<:mia." 100,s. Blood. 111: 446-51.
`Tammnna Syarn et al., "4-1 HB nnd CD28 signaling plays a syner(cid:173)
`gislic role in redirecling u:mbillcal cord blood 'I cells ag,'1insl B-cell
`malignruJcics." 2010 lluman Gene Tl1crapy 21 :75-l\6.
`Till ci al., ''Adopiive immunolhcrapy for i11dl'lcnl 11on-l lodgkin
`lymphoma and mn.nlk cell lympbomu using gcMticnlly 1nodilkd
`autologous CDZO-~~iecific T cells: · 2008. Blood. ll1. 2261-2271.
`Uckrn1, el al, "Dc1ailed stuu.ies on cxprc-ssion and funclion ofCDl9
`surface delcm1.inan t by using 843 monoclonnl anlibody and the
`clinical polenti:Jl of ant·i-CD 19 immunotoxins." 1988. Blood. 7 l; 13-
`29.
`Vinny and Kwon, "Role of 4-1 BB in immune responses." 1998,
`Seminars in Immunology, l0:481-489.
`Willemsen et ul .. "GeMtic Engineering of T Cell Specificity for
`lmmunolhcrnpy of Cancer.'' 2003.1 luman Immunology, 64: 56.f,$,
`Zu1fctey et al.. "M1JLiply altcnuated lcntivtral ViMOr ncbieves
`efficient gene delivery in vivo." 1997, Nature Biot,schnology
`J 5:87 l-S75.
`ChTncsc Patenl Appllcation No. 20 t 1800671 73.X- Office Action
`dated Oct. 22. 20 l4.
`Chinese Palcnl Application No. 20 I [80067173.X- Secontl Ofljce
`Ac11on tlaled J1ul. IO, 10 15,
`Colombia l'al~nl Application No. 13-137636-Colombian resolu(cid:173)
`tion No. 8 176 dated reb. 27, 20 15.
`Colombia l'alcnl /\pplic,ition '\io. n-117636 English lranslatio11
`of Ollice Action of Sep. 5. 2014.
`Cuba Patent Application :Ko. 101310079 00:il-c Action of Apr. l,
`2014,
`Cuba P:11ent A1pplica1ion No , 1013100'79 O llice Aclion of Ocl, 28,
`2014.
`Ft1rasian Region !'ntenl Application No. 201390$47128 omce
`Aclion tlnled Mar, 11. 2015.
`European Paten, Appl 11846757.0 European Search Repon of Dec.
`2. 20 14.
`
`l'inal Office 1\Ction mailed Mnr. 28.
`
`European Pal<:nt Application No. ll846757.0-0.IliceActioo dated
`Aug.. 17.2015,
`Guatemala Pa1enl Applicatlon No. A-20J3-150 E ngli~h lrnnsla.(cid:173)
`liM of Observer's comments of Sep. 17. 1014 .
`. lnpanese Patent AppHcation No. 20 I J -S43J80-0llice Acliorn dated
`Oct. 15, 2015.
`Mexican Pall'nt Applicalion Ko. MXla/201~ '006570 Office
`Action ,falctl Oct. 9. 20 IS.
`New Zealand Pnlenr Applic:il i0n No. 612512 - Firs! E:<Ml Report
`of Nov. 20, 2013.
`rhailand Patent Application No. 1301003 120 Ollice Action of Jul,
`2014,
`U.S. Appl. No. 14'107.302- Fi nal OfticeAction of'Mar. J I. 20 15,
`U.S. Appl. No 141107 .. 102- non-finul Ollice Action of Ser . 30.
`2014,
`U.S. Appl. No, J41567.426-non-final Olli<Je Aclion of Jan, 16,
`20J 5 .
`U.S. Appl. No. J4 '568. l95 non-6nni Ollic.c ,.\ction of Jan . :Jll,
`1015.
`U.S. Appl. No. 14'568,569 non-final Otlkc Action of Jan . 15,
`2015.
`U.S. Appl. No. 13'992,622- non-fina.l Office Aclio n of Jun. 19.
`2015.
`U.S. Appl. No. 13•992,622- Final Office Aclfon of Jan. 5, 2016.
`U.S. Appl. No. 14/465.952- non-tinal ()Dice Aclion of No,v. 20,
`2014.
`U.S. 1\ppl. No, 131938.923
`20)4,
`U.S. Appl. No. 131938,91.3- Finul Ollice Action malled Oci. 8.
`2014,
`U.S. Appl. No. 13/9:18.923-nou-lioal OHicc -\ccioo of Sep. l 9.
`2013.
`U.S. Appl. No. 131938.947- Final Ollice Acti1>n of Sep. l I. 2014.
`U.S. Appl. No. U /938,947- non-final O llicc Acli<>n of Ike. I(>,
`2013.
`U.S. Appl. No . 14/466,096-non-!inul OlficeAction ofCJcl. 8. 1014.
`/\ustm lian Application No. 2011338200 Paten! E.'<ami nnlion
`Rcpor1 No. I. ,L11cd /\pr. 11. 201G.
`Chinese Patent Applicatlon No. 20118006717JX- Third OOke
`Action dated Mat. 28, 2016.
`U.S. Appl. No. 141984.371 non-fuial Ofl:keAction elated Mat. 11 ,
`2016.
`U.S. Appl. No. 141997,042- non-final Ollie" i\dion dated i\ip1'. 13,
`2016.
`U,S. Appl. No. 141997.13(,,_non-final Oflice Action dated Apr. 21 ,
`2016,
`Colombian ra1cn1 Application No 15-80418- 0 .flicc /\cti,m issued
`Dec. 23. 2015.
`Colombian Patent Application No.
`issued Nov, 23. 2015.
`Eumsiru, Palen! Applirntion No, 201390847--00ice Action issued
`Feb, 14. 2016.
`U.S. Apr l. N'o, 131992.622- Final OOice Action i~sued Jan, 5,
`2016.
`"G,mctic1tlly Engine.:red Lymphocyte Therapy in rreating [';1tienls
`with ll-C'ell Leukemia or Lymphoma That is Rcsislanl or Rcfrncto.ry
`lo C'hemolherapy" C'lini,nlTri:ils.gov ltlcntificr NCTO I0:!9366:
`Retrit!vcd from the iotcmeL on Jnn. 29. 2016. l'ound at hltp~:i•\V\\I\V.
`clinicaltrials.gov/ct2/sl1ow1NCTOl029366'/term
`=NCTll 1029366
`&rank- I.
`·"PJl01 Si11dy for Pnlfonts with C hemolherapy Resislnnl or Refrac(cid:173)
`tory CDl9 Leukemia and Lyrnph01na (CART-19)" C linkaJTrials.
`gov Identifier: NCT00891215: Retrieved from the inlemct on Sep,
`2, 2015. Found al hllp://web.archive.org,web,200909030023041
`http:/icli nica ltria ls.govicr;vshow/J\CTOOS9 n 15.
`Apt>liC'hem prod11ct shco1 for RPMl-1640. 1 pages, downloaded
`[)cc. 28. 2015.
`Milone, M. Ill al., Supplementary Matciials and Melhods. Moll Tuer.
`vol. 17. 2009. 7 pages.
`
`:-<\>, 13-t 3 7536- 0llicc ,li.ction
`
`" cited by eJ<amioer
`
`Miltenyi Ex. 1001 Page 5
`
`

`

`"'y J
`I i~
`. I
`Bacterial
`repli.cadon ----i,
`orig:in
`
`.R region
`
`.~
`,<0_1/r
`
`;i:;:,.LT· .. ·R
`. ,.
`
`pELPS 19~:BB--{
`1155.6: hp
`
`,, RRE
`
`·, Trum:::ated
`e.nv
`
`.._EF~lct
`
`~~=
`<i,
`~~
`
`'t
`";\, 3 \LTR {truncateq)
`•:<'(~
`'.
`Bovine GH Poly A
`·<:,\~&"tr .
`.
`... .
`R r,ea-ion 1truncated)~~i<,.,. , __ ~ -....
`~
`\.
`
`''co lg BB.t
`
`'
`
`_..,,
`
`_.,..
`
`v.VPRE
`UJ ltruncatedl
`t
`•
`FMC6:3
`Human CD8a
`Hin~:~nc:f J:M 4~188
`
`Figure 1A
`
`c= .
`~
`--= ~ ;-= !"+-
`
`0 ..,
`....
`:"'°
`r
`0 ....
`
`N
`
`0\
`
`tri =(cid:173)~
`~ ....
`....
`0 ..,
`N
`0\
`
`c:::
`VJ
`--.,.
`',el
`O'I
`~
`""'"' ~
`0
`i:,:;
`N
`
`Miltenyi Ex. 1001 Page 6
`
`

`

`U.S. Patent
`
`Oct. 11, 2016
`
`Sheet 2 of 26
`
`US 9,464,140 B2
`
`l1l
`~ -
`~
`
`.s
`.....
`g~
`
`0.:.
`
`'
`
`t;, .. - ·
`
`Cl) w ~i
`-g
`<.l §
`~ ....
`s:f. ....,
`l5
`p;;
`'
`~i
`~ @
`~ -- &! 1 lt.'!J
`?:
`~£
`8'
`fj
`
`~ I
`
`£.-
`...,.N
`rt,:· .. ,
`<l)'
`>~
`m
`
`!::-
`
`t
`
`_.
`co
`
`OJ
`~
`:::J
`bJJ
`u..
`
`lt1
`>-,
`~-
`0
`
`~~
`
`ID
`::,, ~.g
`,., .
`~m
`r U
`jffi
`t
`'$. ,· k~
`(,:J-~i
`i 01%1
`:cy ·mi
`,I e s:ll'
`::,,
`'
`1
`·~ee
`0 ~ 9l.
`> a
`t
`. - ll :
`ffiz i :,,
`~ ~ %l
`.•
`t;g·i-
`~· ' fl'~
`,: ~ co
`~@J;
`Q ~i'.11~0
`t- ~
`.-a .~~
`€~!
`._,.,(iji
`j •~ ·E
`~S~J .
`~"a!ij~
`~- .
`~ ~~ . j
`·-.. t::: .. ' ·
`_.j ft.
`0
`t;(J .(/) ft.
`(;f:l~-
`(~) if~
`Cl I Ci
`Pi,,...o
`t
`t :i g ,JI· ~· ;
`;j ,(;, ~l'
`
`~
`
`~
`Q ·
`
`"7
`,;::,,·
`>;
`ell
`
`0
`
`- ~
`
`'
`
`'
`
`Miltenyi Ex. 1001 Page 7
`
`

`

`U.S. Patent
`
`Oct.11 . 2016
`
`Sheet 3 of 26
`
`US 9.464,140 B2
`
`.J~Jtl.i8Jl •Mfi◊~P.$l~!llJ $~\f ~A~~p
`JOJ Su!,~HWll-l JOJ na Jl_gl;}~ s~ .;OJ
`lb~~.Jd t:it.i!}~O!lW3:p ~ J~o JP¥
`
`ZJll~oJ.
`&.I jJ~ll,UtlW/1.li>~f>\l~ ,¼J~lltrt:}
`
`UO\~U! ~od '>l;l)UOUi 9
`il.fc!~UOW.; VOO~MJ~qo Al(,flJ.lOfJ
`
`u
`
`~
`(1)
`'--::::,
`tlO
`LL
`
`-5uia~~o}! 1own1.
`AtlfQiQ!!J
`
`Miltenyi Ex. 1001 Page 8
`
`

`

`U.S. Patent
`
`Oct 11, 2016
`
`Sheet 4 of 26
`
`US 9,464,140 B2
`
`t ._ tJii.J i
`
`I
`
`jPill\ I
`
`)li,Slj 1 Ji/. I
`
`jCl\i
`
`Jctlil ,
`
`i ,..
`
`co
`N
`OJ
`I,...
`:J
`tl.O
`u...
`
`<(
`N
`
`~ .,.
`/lit .., ....
`... tl
`i ~ ·,;
`';ii
`~ ~
`.,. .5
`(:;, ~
`$
`
`¥1
`.II')
`Q
`
`i t
`Q
`
`0,. -·
`
`Miltenyi Ex. 1001 Page 9
`
`

`

`U.S. Patent
`
`Oct 11, 2016
`
`Sheet 5 of 26
`
`US 9,464,140 B2
`
`I
`I J
`
`jihfil j I.
`
`►()Iii i !
`
`fll,11, ij. l
`
`I
`
`jliliil!
`
`jiklii I 4-
`
`0
`N
`(lJ
`~ Ill i
`
`LL
`
`~ I
`
`u
`N
`(lJ
`'(cid:173)
`::l
`tlO
`LL
`
`Miltenyi Ex. 1001 Page 10
`
`

`

`U.S. Patent
`
`Oct. 11, 2016
`
`Sheet 6 of 26
`
`US 9,464,140 B2
`
`LL
`N
`OJ
`!....
`::J
`b.O
`LL
`
`UJ
`N
`OJ
`i...
`::J
`b.O
`LL
`
`,
`
`. I 1
`
`\I( 11$\ • MIiii I
`
`(
`
`j,lh i i I
`
`l,hilid i
`
`I
`
`!iiii¥1;
`
`t;
`!
`~-
`0
`
`e.
`""
`
`ij'
`i
`
`<':,
`~
`
`';,,r,r '
`"'''' ''
`,,.
`
`Miltenyi Ex. 1001 Page 11
`
`

`

`U.S. Patent
`
`Oct. 11, 2016
`
`Sheet 7 of 26
`
`US 9,464J40 B2
`
`;,,,
`~
`
`.__ ......... = Cl ·;
`~ ~
`~ ,!E
`it
`0
`~ ·
`::I>. a
`
`·t
`
`~
`
`co
`M
`Q)
`~
`:J
`bD
`LL
`
`tau-H~Q iu~1i ~Jrueu~ mnil
`~QJ.~!fWMS
`
`<C
`M
`Q) ~
`"(cid:173)
`:J
`bD
`LL
`
`,..
`~
`{~ll~~q lt.i!QJJ~!m~p ~#}
`~~Ol}O .Wni/1<$
`.
`
`¢'
`
`1Z
`
`~ --g
`·~ :,
`....
`,E-
`'t§
`Q a
`@ i::,.,
`l'J'
`Q
`
`Miltenyi Ex. 1001 Page 12
`
`

`

`U.S. Patent
`
`Oct 11, 2016
`
`Sheet 8 of 26
`
`US 9,464,140 B2
`
`)
`I I I
`
`u
`M
`C1J g
`I,..
`:J
`tl.O
`u,_
`
`,,..
`
`..
`
`0
`'<'"'
`
`""'
`~
`(~11asaq tl/b-4. ~u~ ~ PIO!}
`aui~o,llo blru~s
`
`Miltenyi Ex. 1001 Page 13
`
`

`

`U.S. Patent
`
`Oct 11, 2016
`
`Sheet 9 of 26
`
`US 9,464,140 B2
`
`~
`0 u
`
`.... --~·...,:~~~tt:\:•,,. '."··'
`r ~,
`I
`
`(()
`Q
`0
`
`Miltenyi Ex. 1001 Page 14
`
`

`

`U.S. Patent
`
`Oct 11, 2016
`
`Sheet 10 of 26
`
`US 9,464,140 B2
`
`co
`"-t'
`Q)
`I...
`::J
`tl.O
`LL.
`
`~~
`c:.J » ·
`I.,.) °\'$
`0
`
`?:
`
`~
`
`l,
`
`,,
`
`~
`
`'
`'
`.,
`<
`
`Miltenyi Ex. 1001 Page 15
`
`

`

`U.S. Patent
`
`Oct 11, 2016
`
`Sheet 11 of 26
`
`US 9,464,140 B2
`
`~ ...
`. B·
`
`~
`.8
`
`,..
`.. ~
`
`r-, a (J
`
`>l>l
`~ ·o .
`l'
`
`~
`Cl ~'
`
`B;J ~
`
`.,.
`~
`Q
`(;
`
`.
`
`.
`
`..
`
`r~
`N
`Q
`I)
`
`~
`0
`~
`
`.
`
`~
`
`ttO:tii
`
`j :~
`
`st-Q:>
`
`$fUD
`
`f,.,
`
`~
`
`',.\
`
`~
`Q
`~
`
`~-♦~d
`
`kQd
`
`:l.1;1:iJ
`
`rs-.
`~
`~ !J
`
`~ -
`
`~-
`
`..
`
`W'©
`
`-~u-::,
`
`·tt()o
`
`••'CM-
`
`at©
`
`~:
`0
`~
`
`P....
`
`t:1
`~
`
`ro.
`>('l,
`8
`
`"'
`It',
`Q
`t.;)
`
`l!i.
`r',I ·
`0
`u
`
`~
`
`a·
`
`.tta~
`
`JZ(l!J
`
`~
`. N ·
`0
`~
`
`t~OP
`
`lt&O
`
`m·
`
`. Q ·
`•U
`
`PJ·Q~
`
`a:-ao
`
`P:®'·
`
`t~tl~
`
`\\
`
`lj
`
`e~J =l
`
`0
`
`•'?.- ~ • ' c-
`
`!
`
`Miltenyi Ex. 1001 Page 16
`
`

`

`U.S. Patent
`
`Oct. 11, 2016
`
`Sheet 12 of 26
`
`US 9,464,140 B2
`
`Figure 4D
`
`NOTARGE,T
`
`U.PNO$
`t);6;Y' 5S
`
`:u.i
`
`n:1
`
`,~,-4,.
`
`lJFN ·Oi
`OAY.16$
`
`,.
`
`S:M
`
`J:}:s?.,:
`
`<l'U'
`
`?l.~4: ·
`
`7:Mt·
`
`8...1~
`
`».~
`
`,,.,
`
`a
`
`$ .1'6'
`
`~Z>
`
`'l>.1•
`
`·$Ml·
`
`K5&2
`
`KSS2. ~
`
`C!P19 < u
`
`NALM~
`
`?MA+
`tONOMY'CI~
`
`~-·~,•
`
`O.'t8:
`
`~n
`
`.(;~1
`
`ll
`
`CDlO?A
`
`Miltenyi Ex. 1001 Page 17
`
`

`

`U.S. Patent
`
`Oct 11, 2016
`
`Sheet 13 of 26
`
`US 9,464,140 B2
`
`<!
`l.f')
`,._
`QJ
`:J
`tlO
`LL
`
`·------------""-+ .ra
`I i i· A . ' I I~·
`\t:W'WJ~A} l,$}· @.tj;1J
`
`Miltenyi Ex. 1001 Page 18
`
`

`

`U.S. Patent
`
`Oct. 11, 2016
`
`Sheet 14 of 26
`
`US 9,464J40 B2
`
`....
`i;;li
`:it
`0.
`~
`
`co
`LI)
`a,
`::l
`0.0
`u..
`
`!,,_
`
`... e
`z
`a. ::,
`
`u
`I.fl
`a,
`::l
`
`!,,_
`
`tl.O ·-
`
`LL.
`
`Miltenyi Ex. 1001 Page 19
`
`

`

`U.S. Patent
`
`Oct 11, 2016
`
`Sheet 15 of 26
`
`US 9,464,140 B2
`
`LL
`
`<(
`\0
`Q)
`~
`:J
`0.01
`LL
`
`u..
`
`Miltenyi Ex. 1001 Page 20
`
`

`

`U.S. Patent
`
`Oct. 11, 2016
`
`Sheet 16 of 26
`
`US 9,464,140 B2
`
`,..
`,.. .
`
`•.
`
`I
`
`..,._.,._..;.,o«.,,..«"-,glt,(.;:.,.•;,:·-1
`
`~L .. __ i:,J
`
`ffl
`
`-11
`
`l :
`
`I i
`
`0
`r-,..
`Q)
`I....
`::l
`b.O
`LL
`
`u r-,..
`
`Q)
`I